Dr. Krishnan Nandabalan is a visionary leader and serial biotech entrepreneur with over two decades of experience in the Pharmaceutical and Biotechnology Industries. His expertise spans Research and Development, Operations, Business Development, Mergers and Acquisitions, and Licensing Strategies.
Currently serving as Chairman & CEO of Invea Therapeutics and President & CEO of AlphaMeld Corporation, Dr. Nandabalan has been instrumental in pioneering the application of Artificial Intelligence (AI) and Machine Learning (ML) to accelerate drug discovery and healthcare innovation. He co-founded BioXcel Therapeutics (NASDAQ: BTAI), playing a pivotal role in its successful spinout.
Throughout his career, Dr. Nandabalan has forged strategic partnerships with global pharmaceutical leaders including AstraZeneca, Biogen, BMS, GSK, Pfizer, Novartis, and Takeda. His strategic vision and scientific acumen have consistently driven innovation at the intersection of Data Science and Medicine.
He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India, and completed his post-doctoral fellowship at Yale University. With 12 issued patents and publications in top-tier journals such as Cell and Science, Dr. Nandabalan brings a rare blend of scientific depth and strategic foresight to VedTechBio’s Advisory Board.
Dr. Ravi Kiron is a seasoned biotech and pharmaceutical leader with deep expertise in scientific innovation and commercialization strategy. As Managing Director at Biopharma Strategy Advisors, he advises life sciences organizations on technology evaluation, partnerships, and strategic growth.
With leadership experience at Cornell University, Pfizer, Johnson & Johnson, and Merck KGaA (EMD Serono), he has successfully translated cutting-edge science into impactful therapeutic and business outcomes. His expertise spans Oncology, CNS, Cardiovascular, Diagnostics, and emerging technologies including AI and next-generation therapeutic platforms.
Dr. Kiron, brings strategic insight, global partnership experience, and innovation leadership to VedTechBio’s Advisory Board, supporting our mission to accelerate AI-driven healthcare advancement.
